Atea Pharmaceuticals (AVIR) Cash from Operations (2019 - 2026)

Atea Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 46391000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 51.79% year-over-year to 46391000.0 in Q1 2026; TTM through Mar 2026 was 147859000.0, a 17.17% decrease from a year earlier, with the FY2025 full-year figure at 132031000.0, up 2.56% from the prior year.
• Cash from Operations retreated to 46391000.0 in Q1 2026 per AVIR's latest filing, from 28223000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 16120000.0 in Q2 2023 and bottomed at 59009000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 29850000.0 (2023), against an average of 30605764.71.
• Biggest YoY gain for Cash from Operations was 71.43% in 2022; the steepest drop was 250.47% in 2022.
• Year by year, Cash from Operations stood at 21545000.0 in 2022, then fell by 1.34% to 21834000.0 in 2023, then plunged by 39.22% to 30397000.0 in 2024, then advanced by 7.15% to 28223000.0 in 2025, then sank by 64.37% to 46391000.0 in 2026.
• Per Business Quant, the three latest AVIR Cash from Operations figures stand at 46391000.0 (Q1 2026), 28223000.0 (Q4 2025), and 40375000.0 (Q3 2025).